Status:

RECRUITING

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

Lead Sponsor:

V-Wave Ltd

Conditions:

Pulmonary Arterial Hypertension

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, dev...

Detailed Description

This is a multi-national, multi-center, prospective, non-randomized, open label trial of patients implanted with the study device. A total of up to 20 patients will be implanted with the study device ...

Eligibility Criteria

Inclusion

  • Main
  • Group 1 PAH (idiopathic, connective tissue disease, HIV, corrected congenital heart disease).
  • WHO Functional Class III or IV symptoms. If WHO Class III, at least 1 High-Risk characteristic or 2 Intermediate-Risk characteristics from the 2015 ESC Guidelines.
  • Receiving maximal available and tolerable pharmacological PAH therapy ≥3 months at a stable dose for ≥1 month.
  • Main

Exclusion

  • Resting oxygen saturation \<90 % without supplemental oxygen corrected for altitude.
  • Mean Right Atrial Pressure \>20 mmHg.
  • Severe restrictive or obstructive lung disease.
  • Evidence of organ dysfunction other than right heart failure.
  • Left ventricular ejection fraction \<40 %.
  • Anatomical anomaly on transesophageal echocardiography or intracardiac echocardiography that precludes implantation of Shunt across fossa ovalis (FO) of the interatrial septum.
  • Inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (IVC) is not patent.
  • Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion Criteria.

Key Trial Info

Start Date :

February 14 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03838445

Start Date

February 14 2020

End Date

December 31 2026

Last Update

June 7 2024

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Keck Medical Center of USC

Los Angeles, California, United States, 90033

2

University of California, San Francisco

San Francisco, California, United States, 94143

3

The Ohio State University Wexner Medical Center - Davis Heart & Lung Research Institute

Columbus, Ohio, United States, 43210

4

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval

Québec, Canada